Moderna
Search results
We at BioNTech believe that the immune system is the fundamental driver for therapeutic success in cancer, and infectious diseases and other serious diseases.
BioNTech was founded in 2008 based on research by Uğur Şahin, Özlem Türeci, [12] and Christoph Huber, [13] with a seed investment of €150 million from MIG Capital and AT Impf. [14] The company's activities focus on the development and production of technologies and drugs for individualized cancer immunotherapy. [3]
Unsere Mission. Mit unserer Grundlagenforschung und der Entwicklung von Immuntherapien möchten wir die Gesundheit der Menschen weltweit verbessern, indem wir das volle Potenzial des Immunsystems nutzen, um Krebs und Infektionskrankheiten zu bekämpfen.
With decades of deep immunology expertise and experience in developing and optimizing mRNA as part of its broad suite of novel technologies, the company is working with the global community to defeat life-threatening and serious diseases such as cancer, COVID-19, malaria and tuberculosis.
May 10, 2021 · BioNTech to establish first regional hub in Asia Pacific region in Singapore. Planned state-of-the-art manufacturing site will support global supply of mRNA-based vaccines and therapeutics and provide a rapid response capability for south east Asia against potential future pandemic threats.
Nov 13, 2022 · The acquisition is part of BioNTech’s expansion strategy to strengthen its global footprint in Asia. Supported by the Singapore Economic Development Board (“EDB”), the facility will serve as BioNTech’s Regional Headquarters and become its first mRNA manufacturing facility in Singapore.
Apr 9, 2020 · Pfizer and BioNTech to jointly develop COVID-19 vaccine, initially in the United States and Europe, and scale-up manufacturing capacity to support global supply. Potential to supply millions of vaccine doses by the end of 2020 subject to technical success of the development program and approval by regulatory authorities, and then ...
May 22, 2024 · Biopharmaceutical New Technologies, or BioNTech, is a global, fully integrated next-generation immunotherapy company pioneering novel therapies for cancer, infectious diseases and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel ...
BioNTech SE. 244,436 followers. 3w. +++ 𝗢𝘂𝗿 𝗺𝗥𝗡𝗔 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗖𝗲𝗻𝘁𝗲𝗿 𝗶𝗻 𝗠𝗲𝗹𝗯𝗼𝘂𝗿𝗻𝗲 𝗵𝗮𝘀 ...
Nov 18, 2020 · The only Grade 3 (severe) solicited adverse events greater than or equal to 2% in frequency after the first or second dose was fatigue at 3.8% and headache at 2.0% following dose 2. Consistent with earlier shared results, older adults tended to report fewer and milder solicited adverse events following vaccination.
